在 sirolimus-eluting 支架植入后,抗血小板治疗和支架血栓形成
Takeshi Kimura1, Takeshi Morimoto, Yoshihisa Nakagawa
1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan. taketaka@kuhp.kyoto-u.ac.jp
Circulation
|February 11, 2009
概括
在药物释放的支架植入后停止使用丁诺皮里丁和阿司匹林显著增加了支架血栓形成的风险. 仅停止提伊诺皮里丁并没有增加这种风险,这表明长期效益有限,超过六个月.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 药物排泄支架 (DES) 植入后停止抗血小板治疗存在风险.
- 经DES后的长期结果和支架血栓形成需要进一步调查.
研究的目的:
- 调查抗血小板治疗中止对支架血栓形成和临床结果的影响.
- 评估与在DES植入后停止丁胺和阿司匹林相关的风险.
主要方法:
- 在日本,对10778名接受西洛林木斯排泄支架的患者进行了观察性研究.
- 在随访期间,可能收集抗血小板治疗状态.
- 对支架血栓的分析和2年后的临床结果.
主要成果:
- 在多次间隔中,停止使用丁皮和阿司匹林显著增加了支架血栓形成的风险.
- 停止单独使用烯二并不增加支架血栓形成率.
- 在24个月的时间里,在丁皮里丁使用者和非使用者之间,死亡或心肌梗塞发生率没有显著差异 (基准分析).
结论:
- 停止双重抗血小板治疗 (丁胺和阿司匹林) 会增加支架血栓形成的风险.
- 暂停单一治疗诺皮里丁似乎不会增加支架血栓形成.
- 锡诺皮里丁治疗在西罗利木斯排泄支架植入后六个月以上的临床益处并不明显.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

